Antiemetic Efficacy of Granisetron: a Randomized Crossover Study in Patients Receiving Cisplatin-containing Intraarterial Chemotherapy

K. Uchida, H. Akaza, K. Hattori, R. Noguchi, F. Kondo, S. Ishikawa, M. Ohtani, S. Hinotsu, K. Koiso
1999 Japanese Journal of Clinical Oncology  
Cisplatin (COOP) is one of the most active chemotherapeutic agents but is among the most emetogenic drugs. The emetic side-effects of COOP-containing intraarterial chemotherapy have not been evaluated in a prospective randomized trial and the efficacy of serotonin antagonists in preventing the emesis associated with this method of COOP administration has not been assessed. Methods: CODP 50 mg/m 2 and methotrexate 30 mg/m 2 were administered every 3 weeks through intraarterial catheters placed
more » ... the bilateral internal iliac arteries. Patients were classified into two groups: granisetron treatment group (group G) and no treatment group (group NG) with the first course of chemotherapy, crossing over with the second course. The patients in group G received granisetron 40 IJ.g/kg by intravenous infusion. Results: Although intraarterial COOP administration produced less emesis than intravenous COOP administration, at the same concentration, gastrointestinal toxicity is still the most unpleasant side-effect for patients. Granisetron administration significantly reduced nausea and vomiting during the acute emetic phase (an evaluation of treatment as very effective and effective was made in 89% in group G and 33% in group NG (P < 0.001). Complete control of emesis was achieved in 68 and 18% of patients in groups G and NG, respectively (P < 0.0001). Conclusion: A single prophylactic infusion of granisetron was effective in preventing the nausea and vomiting associated with intraarterial COOP-containing therapy.
doi:10.1093/jjco/29.2.87 pmid:10089949 fatcat:gb5njgym3fc2lkk5rpuqx52b3m